These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7202826)

  • 1. Inhibition of platelet aggregation in man by indobufen (K 3920).
    Vittoria A; Laghi Pasini F; Messa GL; Di Perri T; Corvi G; Fuccella LM
    J Int Med Res; 1981; 9(1):12-7. PubMed ID: 7202826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology studies with indobufen (K 3920): inhibitor of platelet aggregation.
    Vinazzer H; Fuccella LM
    J Clin Pharmacol; 1980; 20(5-6 Pt 1):316-25. PubMed ID: 7400367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of aspirin and indobufen in healthy volunteers.
    Lee JY; Sung KC; Choi HI
    Platelets; 2016; 27(2):105-9. PubMed ID: 26083594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of in vivo platelet aggregation by indobufen in angina patients during exercise.
    Pogliani EM; Fantasia R; Perini C; Corvi G
    J Int Med Res; 1981; 9(2):113-9. PubMed ID: 7014283
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetic, bioavailability and pharmacodynamic study of indobufen (K 3920), an inhibitor of platelet aggregation, after a single dose in man.
    Fuccella LM; Corvi G; Moro E; Pogliani E; Tamassia V; Tosolini G
    Eur J Clin Pharmacol; 1979 Jun; 15(5):323-7. PubMed ID: 456403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary human pharmacology studies on the inhibition of platelet aggregation by indobufen (K 3920).
    Pogliani E; Corvi G; Mandelli V; Fuccella LM
    Haematologica; 1981 Apr; 66(2):160-70. PubMed ID: 6115794
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of indobufen on occlusion of arteriovenous fistulas and some platelet activity in intermittent peritoneal dialysis patients.
    Dmoszyńska A; Janicki K; Janicka L; Przesmycki K; Sokołowska B; Walter-Croneck A
    Pol J Pharmacol; 1996; 48(3):327-9. PubMed ID: 9112671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and ex vivo effects of indobufen on human platelet aggregation, the release reaction and thromboxane B2 production.
    Cattaneo M; Bevilacqua C; Lecchi A; Mannucci PM
    Haemostasis; 1987; 17(5):293-300. PubMed ID: 3666587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of platelet aggregation by a new synthetic compound: 2-[p-(1-oxo-2-isoindolinyl)phenyl] butyric acid (K 3920).
    Di Perri T; Vittoria A; Laghi Pasini F
    Arzneimittelforschung; 1979; 29(1):104-6. PubMed ID: 582103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical-experimental studies on the inhibition of thrombocyte function with acetylsalicylic acid and with indobufen].
    Vinazzer H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(5-6):783-96. PubMed ID: 94870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific inhibition of 40 K protein phosphorylation in platelet by a new antithrombotic agent, d-indobufen.
    Mamiya S; Hagiwara M; Ishikawa T; Hidaka H
    Thromb Res; 1989 Jun; 54(5):447-56. PubMed ID: 2505401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-thromboglobulin and platelet factor 4 plasma levels during haemodialysis: effect of indobufen.
    Pogliani EM; Colombi M; Cristoforetti G; Valenti G; Miradoli R; Buccianti G
    Pharmatherapeutica; 1982; 3(2):127-32. PubMed ID: 6179101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary studies on indobufen (K 3920). A new inhibitor of platelet aggregation.
    Gürsoy AZ; Yardimci TU; Emekli NB; Ugur MS; Ulutin ON
    Haematologica; 1981 Dec; 66(6):756-67. PubMed ID: 6802717
    [No Abstract]   [Full Text] [Related]  

  • 14. Indobufen (K 3920), a new inhibitor of platelet aggregation: effect of food on bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration to man.
    Tamassia V; Corvi G; Fuccella LM; Moro E; Tosolini G; Tremoli E
    Eur J Clin Pharmacol; 1979 Jun; 15(5):329-33. PubMed ID: 456404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory activity of indobufen (*) on platelet aggregation in vivo.
    Bergamaschi M; Pierucci L; Branzoli U
    Pharmacol Res Commun; 1984 Oct; 16(10):979-85. PubMed ID: 6438651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical contribution to the study of indobufen, a new platelet aggregation inhibitor].
    Ciammaichella A; Luzi M; Pezzi F; Recchia O
    Clin Ter; 1982 Aug; 102(4):387-95. PubMed ID: 6754219
    [No Abstract]   [Full Text] [Related]  

  • 17. Distribution of 14C-labelled 2-[p-(1-oxo-2-isoindolinyl)phenyl]butyric acid, (indobufen or K 3920) in blood, platelets and platelet components.
    Vinazzer H; Zolle I; Fuccella LM; Valzelli G
    Thromb Res; 1980 Feb 1-15; 17(3-4):303-16. PubMed ID: 7368166
    [No Abstract]   [Full Text] [Related]  

  • 18. Indobufen treatment in type IIA hypercholesterolemic subjects: effects on platelet function and malondialdehyde production.
    Tremoli E; Maderna P; Sirtori M; Colli S; Corvi G; Sirtori CR
    Pharmacol Res Commun; 1981 Oct; 13(9):847-59. PubMed ID: 7335762
    [No Abstract]   [Full Text] [Related]  

  • 19. [Evaluation of morning platelet aggregation in patients with ischemic cardiopathy after evening administration of indobufen].
    Craveri A; Lanfredini M; Citella C; Braconaro F; Colombo L
    Minerva Cardioangiol; 1988 Sep; 36(9):411-8. PubMed ID: 3226570
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antiaggregating effect of indobufen. Preliminary results of a study of 20 patients].
    Andriani A; Chiappetta MG; Mannarino E; Mosiello G; Zampa G; Beni A
    Recenti Prog Med; 1986 Dec; 77(12):580-6. PubMed ID: 3563087
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.